Consolidated Statement of Changes in Shareholders Equity For the year ended 30 June 2018 Attributable to owners of the parent Foreign Issued Share currency Nonshare premium Own translation Merger Retained controlling Total capital account shares reserve reserve earnings Total interests equity Year ended 30 June 2017 m m m m m m m m m At 1 July 2016 0.9 172.5 0.1 5.5 1.8 94.0 274.6 2.0 276.6 Profit for the period 26.1 26.1 26.1 Recycle of losses arising on available for sale financial assets 0.3 0.3 0.3 Foreign currency translation differences for foreign operations, net of tax 12.7 12.7 0.2 12.9 Remeasurement of defined benefit pension scheme, net of tax 1.6 1.6 1.6 Total comprehensive income 12.7 28.0 40.7 0.2 40.9 Transactions with owners: Dividends paid 17.7 17.7 17.7 Share-based payments 3.1 3.1 3.1 Shares issued 0.9 0.9 0.9 Acquisition of non-controlling interests 0.6 0.6 Own shares purchased 0.6 0.6 0.6 Total contributions by and distributions to owners 0.9 0.6 14.6 14.3 0.6 14.9 At 30 June 2017 0.9 173.4 0.7 18.2 1.8 107.4 301.0 1.6 302.6 Year ended 30 June 2018 At 1 July 2017 0.9 173.4 0.7 18.2 1.8 107.4 301.0 1.6 302.6 Profit for the period 36.1 36.1 36.1 Foreign currency translation differences for foreign operations, net of tax 0.4 0.4 0.4 Total comprehensive income 0.4 36.1 35.7 35.7 Transactions with owners: Dividends paid 21.8 21.8 21.8 Share-based payments 4.3 4.3 4.3 Shares issued 0.1 185.9 186.0 186.0 Recycle of own shares to retained earnings 0.3 0.3 Acquisition of non-controlling interests 0.2 0.2 1.6 1.8 Total contributions by and distributions to owners 0.1 185.9 0.3 18.0 168.3 1.6 166.7 At 30 June 2018 1.0 359.3 0.4 17.8 1.8 125.5 505.0 505.0 Foreign Currency Translation Reserve The foreign currency translation reserve contains exchange differences on the translation of subsidiaries with a functional currency other than Sterling and exchange gains or losses on the translation of liabilities that hedge the Companys net investment in foreign subsidiaries.
Merger Reserve The merger reserve represents the excess of fair value over nominal value of shares issued in consideration for the acquisition of subsidiaries where statutory merger relief has been applied in the financial statements of the Parent Company.
114 Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2018 www.
